9 results about "Lipid emulsion" patented technology

The present invention relates to glucose solutions for parenteral administration comprising glucose and a pharmaceutically acceptable form of iron, as well as to containers comprising, in separate chambers, said glucose solutions and a lipid emulsion for parenteral administration and / or an amino acid solution for parenteral administration.

The present invention relates to lipid emulsions for parenteral administration comprising an oil phase and a pharmaceutically acceptable form of selenium, as well as to containers comprising, in separate chambers, said emulsions and an amino acid solution for parenteral administration and / or a glucose solution for parenteral administration.

The present invention relates to amino acid solutions for parenteral administration comprising amino acids and a pharmaceutically acceptable form of copper, as well as to containers comprising, in separate chambers, said amino acid solutions and a lipid emulsion for parenteral administration and / or a glucose solution for parenteral administration.

A piperazine substituted phenol derivative and its applications in pharmaceutical chemistry are provided. The compound, depicted by formula I, exhibits excellent salt formation properties and water solubility, meeting formulation requirements. It also has a low minimum effective anesthetic dose, enabling rapid onset and recovery. This addresses the drawbacks of propofol and ciprofol prodrugs and lipid emulsions. The compound shows promise in developing drugs with sedative, hypnotic, and / or anesthetic effects, as well as in drugs for controlling status epilepticus.

The present invention relates to a specific lipid emulsion comprising ≥ 5 % stearidonic acid and ≥ 15 % α-linolenic acid for use in neuroprotection, neuroregeneration and neurodevelopment.

The present disclosure relates to lipid emulsions for parenteral administration, comprising 10 to 30% of a lipid phase comprising soybean oil, medium-chain triglycerides (MCT), olive oil and fish oil and less than 25 mg, preferably less than 20 mg, campesterol, less than 30 mg, preferably less than 25 mg, stigmasterol and less than 120 mg, preferably less than 100 mg, betasitosterol per 100 g of the lipid phase. The present disclosure also relates to the lipid emulsions according to the present disclosure for providing parenteral nutrition, in particular to neonates, as well as to methods for manufacturing the lipid emulsions according to the present disclosure.

A lipid or enzyme-modified lipid emulsion with excellent stability at low temperatures is developed. The lipid or enzyme-modified lipid emulsion includes an aqueous phase comprising 1.0-15 wt % modified starch or a polyglycerol ester of fatty acids (PGE) and 30-50 wt % organic solvent; and an oil phase comprising 1.0-20 wt % lipid or enzyme-modified lipid, such as enzyme-modified butter flavor or enzyme-modified plant oil, and 5.0-25 wt % edible oil. The lipid or enzyme-modified lipid emulsion may further include 0.1-5.0 wt % crystallization inhibitor and / or 0-15 wt % weighting agent. The enzyme-modified butter flavor or enzyme-modified plant oil in the lipid or enzyme-modified lipid emulsion is selected from the group consisting of monoglyceride, diglyceride, triglyceride, and a mixture thereof. A method for preparing the lipid or enzyme-modified lipid emulsion is also developed.

The present disclosure relates to improved lipid emulsions for providing parenteral nutrition, including ready-to-use parenteral nutrition formulations comprising such lipid emulsions. More particularly, the present disclosure is directed to improved lipid formulations or emulsions including multi-chamber containers comprising same, wherein the lipid emulsion contains DHA, EPA, and ARA in an optimized concentration and ratio, optionally in combination with choline and defined levels of phytosterols. The present disclosure further relates to methods of avoiding and / or treating liver damage and / or inflammation, and to methods for improving fatty acid profiles in plasma and certain tissues or organs especially of pediatric patients.

The present disclosure provides lipid emulsions comprising at least 20 percent (w / v) lipid with an average particle size of about 200 to about 300 nm, and use thereof to treat subjects in need of lipid emulsion therapy.